PresentationGreetings. Welcome to the Alkermes Conference Call. My name is Rob, and I'll be your operator for today's call [Operator Instructions] Please note, this conference is being recorded. I'll now turn the conference call over to Sandra Coombs, Senior Vice President of Investor Relations and Corporate Affairs. Sandy, you may now begin.Sandra CoombsSenior Vice President of Corporate Affairs & Investor Relations Welcome to the Alkermes plc conference call to discuss the results of the Vibrance-1 Phase ...

Key Takeaways Alkermes plc (ALKS) reported earnings from continuing operations of 52 cents per share for the second quarter of 2025, which beat the Zacks Consensus Estimate of 41 cents. The company registered earnings of 53 cents per share in the year-ago quarter. Alkermes' total revenues of $390.7 million in the second quarter decreased 2.1% from the year-ago quarter due to lower manufacturing and royalty revenues. The top line, however, comprehensively beat the Zacks Consensus Estimate of $339 million. Ye ...

Core Insights - Alkermes (ALKS) announced positive top-line data from the phase II Vibrance-1 study for its oral orexin 2 receptor agonist, alixorexton, aimed at treating narcolepsy type 1 (NT1) [1][8] - The study demonstrated statistically significant improvements in wakefulness and excessive daytime sleepiness compared to placebo [2][3] - The 6 mg dose of alixorexton was the only one to achieve statistical significance in reducing weekly cataplexy rates, which may have negatively impacted investor sentiment [4] Study Results - Alixorexton treatment across all doses showed a dose-dependent improvement in wakefulness on the Maintenance of Wakefulness Test (MWT), the primary endpoint of the study [2] - Statistically significant improvements in excessive daytime sleepiness were observed at week six on the Epworth Sleepiness Scale, a key secondary endpoint [3] - The 6 mg dose was the only one to achieve statistical significance in improving weekly cataplexy rates, another key secondary endpoint [4] Safety and Tolerability - Treatment with alixorexton was generally safe and well-tolerated across all doses [5] Future Development Plans - Alkermes plans to initiate a global phase III trial for alixorexton in patients with NT1, building on the success of the Vibrance-1 study [9][10] - Alixorexton is also being studied for narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH), with ongoing phase II studies [11][12] Competitive Landscape - Upon potential approval, alixorexton may face competition from Axsome's Sunosi (solriamfetol), which is already marketed for narcolepsy treatment [13] - Other drugs from Jazz Pharmaceuticals, such as Xyrem and Xywav, also hold significant market share in the sleep disorder segment [14]